Valuation: InspireMD

Market Cap 32.83M 28.78M 26.74M 24.55M 46.25M 3.17B 46.97M 318M 124M 1.55B 123M 121M 5.36B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 32.83M 28.78M 26.74M 24.55M 46.25M 3.17B 46.97M 318M 124M 1.55B 123M 121M 5.36B EV / Sales 2026 *
3.16x
EV / Sales 2027 * 1.5x
Free-Float
80.17%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 2019-12-31
Director of Finance/CFO 58 2025-06-24
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 2017-06-01
Director/Board Member 68 2013-02-06
Director/Board Member 62 2019-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.81%+32.01% - - 32.83M
-1.70%-0.59%-20.16%+4.62% 121B
-0.49%+0.45%-0.84%-7.02% 12.65B
-0.15%+0.27%+58.03%+104.19% 8.99B
+8.70%+25.84%-38.71%-66.00% 4.46B
-1.11%-6.30%+0.41%+39.57% 2.68B
-0.70%-0.28%-10.44%-21.88% 1.65B
+0.89%-3.48%-23.40%-32.36% 1.59B
-2.03%+7.71%+0.95%-59.29% 1.56B
Average -0.04%+0.80%-4.27%-4.77% 19.27B
Weighted average by Cap. -1.17%+1.18%-13.91%+6.72%

Financials

2026 *2027 *
Net sales 10.38M 9.09M 8.45M 7.76M 14.61M 1B 14.84M 101M 39.33M 490M 38.95M 38.1M 1.69B 21.92M 19.21M 17.85M 16.39M 30.87M 2.12B 31.35M 212M 83.08M 1.03B 82.27M 80.49M 3.57B
Net income - -
Net Debt - -
Logo InspireMD
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
-